[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341093-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341093-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","preclinical-development-of-novel-pd-l1-tracers-and-first-in-human-study-of-68gaga-nota-rw102-in-patients-with-lung-cancers","Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers","","Background: The PD-1/PD-L1 axis enables immune evasion in cancer. ImmunoPET imaging of PD-L1 expression can support noninvasive patient selection for solid-tumor immunotherapy. Methods: Recombinant human PD-L1 was used to immunize an alpaca, yielding RW102 from VHH clones. ABDRW102 was engineered by fusing RW102 with the albumin binder ABD035. Four PD-L1 tracers with distinct circulation times were assessed in preclinical models and then translated to a first-in-human study in non-small cell lung cancer. Results: RW102 showed high PD-L1 affinity (KD 15.29 pM); ABDRW102 bound PD-L1 and human serum albumin (KD 3.71 and 3.38 pM). Radiotracers enabled same-day and longitudinal PD-L1 imaging. A pilot trial supported safety and diagnostic value, with potential prediction of immune-related adverse events. Conclusions: The validated PD-L1 tracers indicate [68Ga]Ga-NOTA-RW102 immunoPET is promising for differential PD-L1 visualization and translational immunotherapy monitoring.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/preclinical-development-of-novel-pd-l1-tracers-and-first-in-human-study-of-68gaga-nota-rw102-in-patients-with-lung-cancers/341093/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/preclinical-development-of-novel-pd-l1-tracers-and-first-in-human-study-of-68gaga-nota-rw102-in-patients-with-lung-cancers/341093.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of this study?","Question",{"text":63,"@type":64},"To develop PD-L1-targeted immunoPET tracers and evaluate [68Ga]Ga-NOTA-RW102 from preclinical validation through a first-in-human investigation in non-small cell lung cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the PD-L1 targeting binders RW102 and ABDRW102 generated?",{"text":68,"@type":64},"RW102 was selected after immunizing an alpaca with recombinant human PD-L1 and screening VHH clones for high binding affinity. ABDRW102 was engineered by fusing RW102 with the albumin binder ABD035.",{"name":70,"@type":61,"acceptedAnswer":71},"What imaging and clinical outcomes were reported for [68Ga]Ga-NOTA-RW102?",{"text":72,"@type":64},"Preclinically, [68Ga]Ga-NOTA-RW102 enabled same-day visualization of differential PD-L1 expression with specificity. In a pilot clinical trial, [68Ga]Ga-NOTA-RW102 immunoPET showed safety and diagnostic value and may help predict immune-related adverse events during PD-L1-targeted immunotherapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341093,1790203723,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Open access Original research  \n Preclinical development of novel PD-L1  \ntracers and first-in-human study of [68 Ga]Ga-NOTA-RW102 in patients with lung cancers  \nYou Zhang,1 Min Cao,2 Yanfei Wu,3 Sara Malih,4,5 Dong Xu,6 Erpeng Yang,1 Muhsin H Younis,4 Wilson Lin,4 Haitao Zhao  ,1 Cheng Wang,1 Qiufang Liu,7 Jonathan W Engle,4 Mohammad J Rasaee,5 Yihui Guan,3 Gang Huang,1 Jianjun Liu,1 Weibo Cai,4 Fang Xie,3 Weijun Wei  1  \nTo cite: Zhang Y, Cao M, Wu Y, et al. Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga] Ga-NOTA-RW102 in patients with lung cancers. Journal for ImmunoTherapy of Cancer 2024;12:e008794 . doi:10 . 1136/ jitc-2024-008794  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-008794](jitc-2024-008794)) .  \nYZ, MC and YW contributed equally.  \nAccepted 20 March 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nProfessor Weijun Wei; [wwei@shsmu.edu.cn](wwei@shsmu.edu.cn)  \nFang Xie; [fangxie@fudan.edu.cn](fangxie@fudan.edu.cn)  \nProfessor Jianjun Liu; [nuclearj@163.com](nuclearj@163.com)  \nDr Weibo Cai;  \n[wcai@uwhealth.org](wcai@uwhealth.org)  \nABSTRACT  \nBackground The programmed cell death protein-1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis critically facilitates cancer cells’ immune evasion. Antibody therapeutics targeting the PD-1/PD-L1 axis have shown remarkable efficacy in various tumors. Immunopositron emission tomography (ImmunoPET) imaging of PD-L1 expression may help reshape solid tumors’immunotherapy landscape.  \nMethods By immunizing an alpaca with recombinant human PD-L1, three clones of the variable domain of the heavy chain of heavy-chain only antibody (VHH) were screened, and RW102 with high binding affinity was selected for further studies. ABDRW102, a VHH derivative, was further engineered by fusing RW102 with the albumin binder ABD035. Based on the two targeting vectors, four PD-L1-specific tracers ([68Ga]Ga-NOTA-RW102,[68Ga] Ga-NOTA-ABDRW102,[64Cu]Cu-NOTA-ABDRW102, and [89Zr]Zr-DFO-ABDRW102) with different circulation times were developed. The diagnostic efficacies were thoroughly evaluated in preclinical solid tumor models, followed by a first-in-human translational investigation of [68Ga]GaNOTA-RW102 in patients with non-small cell lung cancer (NSCLC) .  \nResults While RW102 has a high binding affinity to PDL1 with an excellent KD value of 15.29 pM, ABDRW102 simultaneously binds to human PD-L1 and human serum albumin with an excellent KD value of 3.71 pM and 3.38 pM, respectively. Radiotracers derived from RW102 and ABDRW102 have different in vivo circulation times. In preclinical studies,[68Ga]Ga-NOTA-RW102 immunoPET imaging allowed same-day annotation of differential PD-L1 expression with specificity, while [64Cu]Cu-NOTAABDRW102 and [89Zr]Zr-DFO-ABDRW102 enabled longitudinal visualization of PD-L1 . More importantly, a pilot clinical trial shows the safety and diagnostic value of [68Ga]Ga-NOTA-RW102 immunoPET imaging in patients with NSCLCs and its potential to predict immune-related adverse effects following PD-L1-targeted immunotherapies.  \nConclusions We developed and validated a series of PD-L1-targeted tracers. Initial preclinical and clinical evidence indicates that immunoPET imaging with [68Ga] Ga-NOTA-RW102 holds promise in visualizing differential  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Programmed death receptor ligand 1 (PD-L1) -targeted antibody therapeutics are effective for some tumors, but patient response varies. Molecular imaging of PD-L1 expression can aid in patient selection and response prediction.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This study introduces four VHH-derived immunopositron emission tomography (immu","cbCaitE7BlwpJnEh","https://ap.wps.com/l/cbCaitE7BlwpJnEh","pdf",11237577,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Background\n# Trial registration","[{\"question\":\"What is the main goal of this study?\",\"answer\":\"To develop PD-L1-targeted immunoPET tracers and evaluate [68Ga]Ga-NOTA-RW102 from preclinical validation through a first-in-human investigation in non-small cell lung cancer.\"},{\"question\":\"How were the PD-L1 targeting binders RW102 and ABDRW102 generated?\",\"answer\":\"RW102 was selected after immunizing an alpaca with recombinant human PD-L1 and screening VHH clones for high binding affinity. ABDRW102 was engineered by fusing RW102 with the albumin binder ABD035.\"},{\"question\":\"What imaging and clinical outcomes were reported for [68Ga]Ga-NOTA-RW102?\",\"answer\":\"Preclinically, [68Ga]Ga-NOTA-RW102 enabled same-day visualization of differential PD-L1 expression with specificity. In a pilot clinical trial, [68Ga]Ga-NOTA-RW102 immunoPET showed safety and diagnostic value and may help predict immune-related adverse events during PD-L1-targeted immunotherapies.\"}]","Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers | PDF",1790040282,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/969bf7adeaf575f70de5e18703a24b3f.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b78eae67b20ace2887d28729c9afb90b.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca6f1c8e6a7f646871b555a45f6c56af.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e734128cea07b01717fef1be224ad3e7.webp",980,1306]